Therapy for chronic hepatitis C

A. Pár, L. Telegdy, Lajos Dalmi, Eva Müller

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/aims: In Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the interferon therapy. Methods: a total of 993 patients - virtually the entire Hungarian hepatitis C patient population who had been referred for interferon treatment - were included in the program. Actually, the sustained efficacy of the therapy was evaluated in 724 cases. Treatment protocols (dose of interferon and duration of therapy) have changed with time from a weekly dose of 3 × 3 MU IFN for 6 months in the first period, to 3 × 3-5 MU for 12 months in the second period, and finally in the third period a combination therapy with ribavirin has also been introduced. Results: in the first period, the end-of-treatment response (ETR) was 35%, sustained response (SR) 13%, the second phase schedule resulted in 42% ETR and 22% SR, while in the third period, ETR was 49% and SR 36%, respectively. Fibrosis in histology and baseline pretreatment HCV-RNA level appeared as predictors of response. The duration of treatment and the total dose of interferon exerted a moderate effect on therapeutic efficacy. Neither age nor gender influenced the outcome. Conclusions: our results - obtained in a Central East European country - are in accordance with findings of suboptimal efficacy of traditional interferon monotherapy for chronic hepatitis C reported in the West, and suggest the benefit of the combination treatment of interferon with ribavirin.

Original languageEnglish
Pages (from-to)399-405
Number of pages7
JournalJournal of Physiology Paris
Volume95
Issue number1-6
DOIs
Publication statusPublished - 2001

Fingerprint

Chronic Hepatitis C
Interferons
Therapeutics
Ribavirin
Hungary
Therapeutic Uses
Gastroenterology
Hepatitis C
Clinical Protocols
Histology
Appointments and Schedules
Fibrosis
RNA

Keywords

  • Chronic hepatitis C
  • Hungary
  • Ribavirin
  • Treatment interferon

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology (medical)

Cite this

Therapy for chronic hepatitis C. / Pár, A.; Telegdy, L.; Dalmi, Lajos; Müller, Eva.

In: Journal of Physiology Paris, Vol. 95, No. 1-6, 2001, p. 399-405.

Research output: Contribution to journalArticle

Pár, A. ; Telegdy, L. ; Dalmi, Lajos ; Müller, Eva. / Therapy for chronic hepatitis C. In: Journal of Physiology Paris. 2001 ; Vol. 95, No. 1-6. pp. 399-405.
@article{5b6d0a3852fe4843a441b4dc639067db,
title = "Therapy for chronic hepatitis C",
abstract = "Background/aims: In Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the interferon therapy. Methods: a total of 993 patients - virtually the entire Hungarian hepatitis C patient population who had been referred for interferon treatment - were included in the program. Actually, the sustained efficacy of the therapy was evaluated in 724 cases. Treatment protocols (dose of interferon and duration of therapy) have changed with time from a weekly dose of 3 × 3 MU IFN for 6 months in the first period, to 3 × 3-5 MU for 12 months in the second period, and finally in the third period a combination therapy with ribavirin has also been introduced. Results: in the first period, the end-of-treatment response (ETR) was 35{\%}, sustained response (SR) 13{\%}, the second phase schedule resulted in 42{\%} ETR and 22{\%} SR, while in the third period, ETR was 49{\%} and SR 36{\%}, respectively. Fibrosis in histology and baseline pretreatment HCV-RNA level appeared as predictors of response. The duration of treatment and the total dose of interferon exerted a moderate effect on therapeutic efficacy. Neither age nor gender influenced the outcome. Conclusions: our results - obtained in a Central East European country - are in accordance with findings of suboptimal efficacy of traditional interferon monotherapy for chronic hepatitis C reported in the West, and suggest the benefit of the combination treatment of interferon with ribavirin.",
keywords = "Chronic hepatitis C, Hungary, Ribavirin, Treatment interferon",
author = "A. P{\'a}r and L. Telegdy and Lajos Dalmi and Eva M{\"u}ller",
year = "2001",
doi = "10.1016/S0928-4257(01)00054-7",
language = "English",
volume = "95",
pages = "399--405",
journal = "Journal de Physiologie",
issn = "0928-4257",
publisher = "Elsevier Masson SAS",
number = "1-6",

}

TY - JOUR

T1 - Therapy for chronic hepatitis C

AU - Pár, A.

AU - Telegdy, L.

AU - Dalmi, Lajos

AU - Müller, Eva

PY - 2001

Y1 - 2001

N2 - Background/aims: In Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the interferon therapy. Methods: a total of 993 patients - virtually the entire Hungarian hepatitis C patient population who had been referred for interferon treatment - were included in the program. Actually, the sustained efficacy of the therapy was evaluated in 724 cases. Treatment protocols (dose of interferon and duration of therapy) have changed with time from a weekly dose of 3 × 3 MU IFN for 6 months in the first period, to 3 × 3-5 MU for 12 months in the second period, and finally in the third period a combination therapy with ribavirin has also been introduced. Results: in the first period, the end-of-treatment response (ETR) was 35%, sustained response (SR) 13%, the second phase schedule resulted in 42% ETR and 22% SR, while in the third period, ETR was 49% and SR 36%, respectively. Fibrosis in histology and baseline pretreatment HCV-RNA level appeared as predictors of response. The duration of treatment and the total dose of interferon exerted a moderate effect on therapeutic efficacy. Neither age nor gender influenced the outcome. Conclusions: our results - obtained in a Central East European country - are in accordance with findings of suboptimal efficacy of traditional interferon monotherapy for chronic hepatitis C reported in the West, and suggest the benefit of the combination treatment of interferon with ribavirin.

AB - Background/aims: In Hungary, over the past 5 years more than 900 patients with chronic hepatitis C have been examined for treatment with interferon at 16 major hepatology centres, using unified diagnostic and therapeutical criteria. Authors give an account of their experiences on the clinical features of patients with chronic hepatitis C and report the results of the interferon therapy. Methods: a total of 993 patients - virtually the entire Hungarian hepatitis C patient population who had been referred for interferon treatment - were included in the program. Actually, the sustained efficacy of the therapy was evaluated in 724 cases. Treatment protocols (dose of interferon and duration of therapy) have changed with time from a weekly dose of 3 × 3 MU IFN for 6 months in the first period, to 3 × 3-5 MU for 12 months in the second period, and finally in the third period a combination therapy with ribavirin has also been introduced. Results: in the first period, the end-of-treatment response (ETR) was 35%, sustained response (SR) 13%, the second phase schedule resulted in 42% ETR and 22% SR, while in the third period, ETR was 49% and SR 36%, respectively. Fibrosis in histology and baseline pretreatment HCV-RNA level appeared as predictors of response. The duration of treatment and the total dose of interferon exerted a moderate effect on therapeutic efficacy. Neither age nor gender influenced the outcome. Conclusions: our results - obtained in a Central East European country - are in accordance with findings of suboptimal efficacy of traditional interferon monotherapy for chronic hepatitis C reported in the West, and suggest the benefit of the combination treatment of interferon with ribavirin.

KW - Chronic hepatitis C

KW - Hungary

KW - Ribavirin

KW - Treatment interferon

UR - http://www.scopus.com/inward/record.url?scp=0034749916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034749916&partnerID=8YFLogxK

U2 - 10.1016/S0928-4257(01)00054-7

DO - 10.1016/S0928-4257(01)00054-7

M3 - Article

C2 - 11595466

AN - SCOPUS:0034749916

VL - 95

SP - 399

EP - 405

JO - Journal de Physiologie

JF - Journal de Physiologie

SN - 0928-4257

IS - 1-6

ER -